Acurx Pharmaceuticals (NASDAQ:ACXP) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Acurx Pharmaceuticals (NASDAQ:ACXP – Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.03), FiscalAI reports.

Acurx Pharmaceuticals Trading Up 4.1%

Shares of ACXP traded up $0.09 during midday trading on Monday, reaching $2.18. 101,519 shares of the company were exchanged, compared to its average volume of 2,198,020. The stock has a 50-day moving average price of $3.04 and a 200-day moving average price of $3.37. The company has a market cap of $6.22 million, a price-to-earnings ratio of -0.39 and a beta of -2.09. Acurx Pharmaceuticals has a 1-year low of $1.33 and a 1-year high of $21.00.

Get Acurx Pharmaceuticals alerts:

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Armistice Capital LLC acquired a new position in shares of Acurx Pharmaceuticals during the second quarter worth about $551,000. Millennium Management LLC acquired a new position in shares of Acurx Pharmaceuticals in the fourth quarter worth about $103,000. Geode Capital Management LLC acquired a new position in shares of Acurx Pharmaceuticals in the fourth quarter worth about $31,000. Finally, Jane Street Group LLC acquired a new position in shares of Acurx Pharmaceuticals in the fourth quarter worth about $27,000. Institutional investors and hedge funds own 11.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. Wall Street Zen upgraded Acurx Pharmaceuticals to a “sell” rating in a report on Saturday, April 25th. Weiss Ratings restated a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a report on Monday, April 20th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $31.00.

Get Our Latest Research Report on ACXP

About Acurx Pharmaceuticals

(Get Free Report)

Acurx Pharmaceuticals, Inc, headquartered in King of Prussia, Pennsylvania, is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel anti‐infective therapies. The company’s research platform leverages insights into bacterial virulence regulation and quorum sensing pathways to design small-molecule candidates aimed at reducing pathogen toxicity and biofilm formation. By targeting key mechanisms of infection rather than bacterial viability alone, Acurx seeks to offer differentiated treatment options that may help address the growing challenge of antibiotic resistance.

Acurx’s lead product candidates are being developed to treat acute bacterial skin and skin structure infections (ABSSSI), including cases caused by drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA).

Read More

• Five stocks we like better than Acurx Pharmaceuticals
• Before the Moon Base Gets Built, These 4 Companies Win
• Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
• 3 Stocks That Win If Inflation Surprises to the Downside
• MercadoLibre Boldly Invests in Growth: Discount Deepens

Receive News & Ratings for Acurx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acurx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.